We offers you solutions for accurate, reproducible and qualitatively outstanding aids for patient support and patient immobilisation.
We leverage our broad base of innovative products and services to offer the most effective, state-of-the-art radiotherapy positioning solutions. Discover how we are advancing patient care in a variety of ways by exploring the information below.
We specialises in niche products in the field of innovative diagnostics. Our focus is on new methods relating to current and future diagnosis modalities.
We are driven to provide care that cures and comforts, research that informs the world, and education that enlightens and enables future generations. We proudly stand on our rich history and use it as a platform from which to embrace discovery and change.
Through our products and by bringing planning modalities such as computer tomography (CT) and positron emission tomography (PET) closer together, we can give you access to new alternatives for optimizing cancer treatment.
We are committed to making each decision, whether related to patient care, research, education or administration, based on standards that are thoughtful, informed, honest, transparent when appropriate and always respectful of privacy.
The Innovative Medicines Initiative (IMI) is a European initiative to improve the competitive situation of the European Union in the field of pharmaceutical research. The IMI is a joint initiative (public-private partnership) of the DG Research of the European Commission, representing the European Communities, and the European Federation of Pharmaceutical Industries and Associations (EFPIA). IMI is laid out as a Joint Technology Initiative within the Seventh Framework Programme. Michel Goldman was the first executive director, from September 2009 until December 2014.
The Innovative Medicines Initiative is aimed towards removing research bottlenecks in the current drug development process. The IMI Joint Technology Initiative (IMI JTI), to be implemented by the IMI Joint Undertaking is meant to address these research bottlenecks. Its €2bn budget makes it the largest biomedical public-private partnership in the world.
Artificial Intelligence (AI) has the power to improve healthcare delivery across the continuum of care. AI can more quickly identify hemorrhages on CT scan in the emergency department; it can make surgeries safer in the operating room, reduce mortality in intensive care units; and it can help patients recover faster after being discharged. Artificial Intelligence could also assist emergency medical service (EMS) providers in treatment and triage …
The post Artificial Intelligence (AI) coming to Ambulances appeared first on Pittsburgh Life Sciences Greenhouse.
When does disclosing a secret actually help the secret-keeper? In the world of patents and patent protection, it can be a key strategy. Most entrepreneurs understand that an invention must be truly novel to receive a patent. According to the U.S. Patent and Trademark Office (uspto.gov), an invention cannot be one that has been previously “patented, described in a printed …
The post Using Public Disclosures to Prevent Competitive Patents appeared first on Pittsburgh Life Sciences Greenhouse.
As a mentor to young professionals, hosting transatlantic partnerships represents a special honor. Transatlantic mentoring programs strengthen entrepreneurship in the U.S. and abroad. The Young Transatlantic Innovation Leaders Initiative (YTILI) connects European and Eurasian young entrepreneurs with U.S. mentors in cities across the country and is sponsored by the German Marshall Fund of the U.S. and the U.S. Department of …
The post PLSG Participates in Mentoring International Young Entrepreneurs appeared first on Pittsburgh Life Sciences Greenhouse.
PLSG Recognizes Advisory Board Member’s Selection to “30 Under 30” Class Carmelo Montalvo Serves on PLSG’s Under 40, Underserved Advisory Board PITTSBURGH (July 31, 2018)—Carmelo Montalvo, a member of the Pittsburgh Life Sciences Greenhouse (PLSG) Under 40, Underserved Advisory Board, was recently named by the Pittsburgh Business Times to its 2018 “30 Under 30” Class of civic and business leaders. …
The post PLSG Recognizes Advisory Board Member’s Selection to “30 Under 30” Class appeared first on Pittsburgh Life Sciences Greenhouse.
The United Nations defines community development as “a process where community members come together to take collective action and generate solutions to common problems.” Each of us, as individuals, plays a critical role in community development. It is up to each of us to help our communities to thrive and grow for the betterment of all members; to ensure that our region not …
The post Can you really create a “community?” appeared first on Pittsburgh Life Sciences Greenhouse.
IDvet offers an innovative and comprehensive range of mycoplasma diagnostic tests, including both ELISA and PCR kits. The article presents data which demonstrates the advantages offered by the IDvet mycoplasma ELISAs. The ELISA range offers a number of advantages: High exclusivity, with no cross-reactions between different mycoplasmas; Early and long-term antibody detection and […]
The post High performance tests for avian mycoplasmosis appeared first on IDVet.
We provide outstanding customer service and technical support thanks to our distribution network spanning all continents. By adapting products to meet your needs, rapidly responding to your queries, providing free supplementary liquid reagents, and assisting you in kit use and result interpretation, IDvet is with you at every step.
The post Exceptional customer service appeared first on IDVet.
With highly pathogenic H5N8 rapidly spreading throughout Europe, IDvet offers a range of highly specific and sensitive Influenza ELISAs to efficiently monitor spread of the disease. The ID Screen® Influenza H5 competitive ELISA has been validated by several European reference laboratories to detect new circulating clades, including H5N8. The test may be used to […]
The post H5N8 avian influenza outbreaks: efficient tools for disease monitoring and serotyping appeared first on IDVet.
Since IDvet’s creation in 2004, we have grown rapidly, constantly expanding our global distribution network. As a privately owned enterprise, our financial independence allows us to make rapid decisions in reaction to changes in market needs around the world. With exports to over 80 countries, we have established ourselves as a significant player in the […]
The post Born global appeared first on IDVet.
Click on the image below to zoom or download our latest press release!
The post The only commercial NDV ELISA validated for use with HVT-ND vector vaccines! appeared first on IDVet.
